BioCentury
ARTICLE | Clinical News

DxTerity type I interferon biomarker study, launch bolsters lupus patient stratification

November 11, 2019 11:46 PM UTC
Updated on Nov 11, 2019 at 11:50 PM UTC

Data supporting the commercial launch of DxTerity’s type I interferon gene expression test in systemic lupus erythematosus (SLE) could lower barriers to signal detection in clinical trials by identifying patients who stand to benefit most from new therapies.

The presentation came Monday as AstraZeneca plc (LSE:AZN; NYSE:AZN) announced positive Phase III data for anifrolumab, its mAb against the type I IFN receptor, to be presented Tuesday. Data are being presented at the American College of Rheumatology (ACR) annual meeting in Atlanta...

BCIQ Company Profiles

DxTerity Diagnostics Inc.